P2RY12 and acute coronary syndrome: In the AUGUSTUS trial, patients with NVAF and acute coronary syndrome or PCI treated with apixaban and a P2Y12 inhibitor showed lesser bleeding and fewer hospitalizations than those treated with warfarin and dual antiplatelets (26).